Australia's most trusted
source of pharma news
Thursday, 13 November 2025
Posted 13 November 2026 AM
MSD is winning the race to bring the first oral PCSK9 inhibitor to market, after its daily pill enlicitide decanoate produced similar results to existing injectables in two Phase 3 trials.
Both MSD and AstraZeneca are developing PCSK9 inhibitor once-daily pills. Sales of the three approved injectable PCSK9 inhibitors - Amgen’s Repatha, Sanofi’s Praluent and Novartis’s Leqvio - are growing but have failed to meet expectations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.